Get Ultimate PDF of In-Vitro Diagnostics Market
According to The Insight Partners market research study titled “In-Vitro Diagnostics Market Forecast to 2027 – COVID-19 Impact and Global Analysis – by Product & Service, Technology, Application, and End User,” the global in-vitro diagnostics market is expected to reach US$ 90,656.80 million by 2027 from US$ 63,746.63 million in 2019. The market is estimated to grow at a CAGR of 4.5% from 2020 to 2027. The report highlights the trends prevalent in the global in-vitro diagnostics market and the factors driving the market along with those that act as deterrents to its growth.
In terms of product & services, the in-vitro diagnostics
market is segmented into instruments, reagents & kits, and software &
services. In 2019, the reagents & kits segment held a largest market share
of the in-vitro diagnostics market. This segment is also expected to dominate
the market during the forecast period owing to increasing number of diagnostics
tests and rising prevalence of chronic conditions. Moreover, the instruments
segment is anticipated to witness considerable growth rate during the forecast
period. Certain factors, such as developing healthcare infrastructure and
growing demand for rapid disease diagnosis, are expected to drive the segment.
Download the Free PDF Sample Here:
https://www.theinsightpartners.com/sample/TIPBT00002657/
Increasing prevalence of chronic and infectious diseases,
growing geriatric population, and rising demand for in-vitro diagnostics during
COVID-19 pandemic are driving the market. However, the lack of healthcare
infrastructure and reimbursement policies is likely to have a negative impact
on the growth of the market in the coming years.
Prominent players operating in in-vitro diagnostics market
include F. Hoffmann-la Roche Ltd.; Danaher; Abbott; Siemens AG; Sysmex
Corporation; Thermo Fisher Scientific, Inc.; BD; Biomérieux SA; Bio-Rad
Laboratories, INC.; and Qiagen. The market players are focused toward bringing
new and innovative products to sustain their position in the market. For
instance, in January 2021, Roche announced that it has launched two CE-IVD,
which are its automated digital pathology algorithms, uPath HER2 (4B5) image
analysis and uPath Dual ISH image analysis for breast cancer. It is likely to
help in determining the best treatment strategy for each patient. The image
analysis algorithms uses artificial intelligence to support pathologists in
making faster, more accurate patient diagnoses in breast cancer.
About Us:
The Insight Partners is a one stop industry research
provider of actionable intelligence. We help our clients in getting solutions
to their research requirements through our syndicated and consulting research
services. We specialize in industries such as Semiconductor and Electronics,
Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare
IT, Manufacturing and Construction, Medical Device, Technology, Media and
Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would
like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876
Comments
Post a Comment